Skip to main content

Day: August 26, 2024

Construction of a new building nearby Vilnius Akropolis is completed – it became home for the expanded and revamped Sportland store  

Akropolis Vilnius SportlandAkropolis Vilnius SportlandA new commercial building of 480 sq. m has been constructed nearby Vilnius Akropolis. It houses Sportland – the expanded and modernised store offering sports and athleisure wear fashion brands. The previous premises of the shop have been expanded by connecting them to the new building, which has led to the increase of the store area to over 2,000 sq. m, making the store the biggest and most modern Sportland store in Lithuania. “We keep investing into the upgrade of the shopping and entertainment centres Akropolis, with focus on attracting new brands customers like, opening new and revamped stores and points of service. We are delighted that the increased area of the shopping and entertainment centre enabled choosing namely Akropolis as the place for the largest and most modern...

Continue reading

Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases

20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) Data from landmark Phase 3 trials for Dupixent in COPD reinforce exacerbation reduction and improvement in lung function compared to placebo, and provide new assessments on health-related quality of life across patient subgroups Additional presentations spotlight a novel asthma imaging study showing the early impact of Dupixent on clinical remission, airway remodeling and mucus plugging starting at 4 weeks, as well as data from investigational therapy itepekimab in former smokers with COPD TARRYTOWN, N.Y., Aug. 26, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced 20 abstracts across Dupixent® (dupilumab) and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.